Late Stage Autoimmune Pipeline Will Unlock Transformational Long Term Upside

Catalysts

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company advancing a diversified portfolio of late stage medicines targeting large, underserved immunology and specialty disease markets.

What are the underlying business or industry changes driving this perspective?

• Multiple pending late stage readouts and launches for brepocitinib and IMVT-1402 across dermatomyositis, noninfectious uveitis, Graves' disease and other autoimmune indications position Roivant to convert its broad clinical pipeline into a series of commercial assets over the next 36 months. This supports a potential step change in revenue and operating scale.
• The growing medical and regulatory focus on steroid sparing regimens in chronic autoimmune disease, exemplified by brepocitinib data showing deep responses with meaningful steroid reduction, creates an environment where differentiated oral agents can rapidly become standard of care. This may lift pricing power and long term net margins.
• Deep IgG lowering with IMVT-1402 that appears to translate into durable benefit in Graves' disease and potentially other antibody driven conditions offers a clear competitive position within the FcRn class. This may support premium positioning, higher peak sales per indication and improved earnings visibility.
• Expansion of diagnostic capabilities and physician awareness in under treated autoimmune populations such as dermatomyositis, Sjögren's and Graves' disease is enlarging the addressable market for targeted therapies. This could amplify the revenue impact of each successful launch in Roivant's portfolio.
• A balance sheet with 4.4 billion dollars of cash, no debt, and an authorized 500 million dollar capital return program provides Roivant with resources to fund its path to potential profitability, selectively in license additional programs and absorb launch costs without dilutive financing. This may support long term earnings growth and shareholder returns.

Assumptions

This narrative explores a more optimistic perspective on Roivant Sciences compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Roivant Sciences's revenue will grow by 395.8% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -3448.2% today to 11.8% in 3 years time.
• The bullish analysts expect earnings to reach $292.3 million (and earnings per share of $0.22) by about December 2028, up from $-701.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-1.4 billion.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 88.3x on those 2028 earnings, up from -21.9x today. This future PE is greater than the current PE for the US Biotechs industry at 19.0x.
• The bullish analysts expect the number of shares outstanding to decline by 2.53% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.44%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The long term success of Roivant’s pipeline is heavily dependent on positive outcomes from multiple registrational and proof of concept trials across brepocitinib, IMVT-1402 and Pulmovant. Any late stage failures or merely modest efficacy versus existing standards of care could limit adoption and shrink the expected peak patient base, putting downward pressure on long term revenue and earnings growth.
• Rapidly intensifying competition in key autoimmune indications from established FcRn players and other novel mechanisms such as IGF 1R, IL 6 and CAR T approaches may erode Roivant’s hoped for first in class and best in class positioning. This could force more restrictive pricing or higher commercial spend to defend share, which would cap revenue upside and compress net margins over time.
• The evolving safety and tolerability expectations for chronic immunomodulatory therapies, particularly in large, earlier line populations like Graves’ disease and Sjögren’s, raise the risk that regulators or prescribers demand more conservative use or extensive post marketing data. This could slow uptake and extend payback periods on R and D, which would delay the path to sustainable positive earnings.
• While management expects the current 4.4 billion dollars cash balance to fund the pipeline to profitability, prolonged launch curves in rare and specialty indications, coupled with higher than anticipated commercial and litigation expenses, could exhaust balance sheet flexibility and necessitate future equity or debt raises at unfavorable terms. This could dilute shareholders and weaken earnings per share progression.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Roivant Sciences is $32.31, which represents up to two standard deviations above the consensus price target of $25.64. This valuation is based on what can be assumed as the expectations of Roivant Sciences's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $33.0, and the most bearish reporting a price target of just $21.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2028, revenues will be $2.5 billion, earnings will come to $292.3 million, and it would be trading on a PE ratio of 88.3x, assuming you use a discount rate of 7.4%.
  
• Given the current share price of $22.1, the analyst price target of $32.31 is 31.6% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.